Tag Archives: Big Pharma
Tufts R&D Outlook for 2011: Pain Mixed with Promise
The Tufts Center for Drug Development issues its annual assessment of the state of R&D in Big Pharma, noting that industry faces a cumulative tide of challenges marked by a dramatic reversal in societal attitudes toward risk. Productivity gaps in the pipeline aside, perhaps the biggest problem is political — convincing stakeholders to strive for [...]
Posted in FDA, Gene therapy, R&D, Regulatory Also tagged FDA, forecast, monoclonal antibodies, R&D, risk sharing, Tufts Center for Drug Development 1 Comment
New Year Night Stalkers: What Will Keep the C-Suiters Awake in 2011
New Year Night Stalkers
Eight Strategic Issues that Should Keep “C Suiters” Reaching for the NoDoz in 2011
The consensus is that 2011 will be a bad year for big pharma. It must confront a breaking wave of patent expirations, while fiscal retrenchment has created an innovation cycle in reverse as payers find new ways to curb [...]
Posted in Manufacturing, Marketing, R&D, Regulatory, Strategy, Technology, compliance Also tagged 2011, C-Suite 5 Comments
2010: A Year of Big Layoffs for Big Pharma
What are the factors that are contributing to the layoffs that have taken place at virtually all the Big Pharma companies this year?
According to the newly released Job-Cut Announcement Report from outplacement consultancy firm Challenger, Gray & Christmas, pharma has cut more than 6,000 jobs in September alone, and more than 43,000 so far this [...]
Is There Life After Big Pharma?
Guest blog by Pharm Exec Europe’s Jacky Law.
It’s hard to get precise figures of how many people have been taken off the payroll at pharma and biotech companies recently. According to staffing firm, Challender, Gray and Christmas, the combined industries shed 58,969 jobs in the first nine months of 2009, 15,000 more than the whole [...]
Posted in Corporate Responsibility, Deals, Europe, Global, Guest Blog Also tagged downturn, in-licensing, Medivation, pharma. layoffs, redundancies Leave a comment

The Seven-Billion Society: What's In It For Pharma?